The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Drugs for Anti-Infective-Global Market Insights and Sales Trends 2025

Drugs for Anti-Infective-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1838547

No of Pages : 111

Synopsis
Something capable of acting against infection, by inhibiting the spread of an infectious agent or by killing the infectious agent outright. Anti-infective is a general term that encompasses antibacterials, antibiotics, antifungals, antiprotozoans and antivirals.
The global Drugs for Anti-Infective market size is expected to reach US$ 272130 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Drugs for Anti-Infective in various end use industries. The expanding demands from the Hospital, Drugs Store and Other, are propelling Drugs for Anti-Infective market. OTC, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Rx Drugs segment is estimated at % CAGR for the next seven-year period.
The Anti-Infective Drugs market refers to the pharmaceuticals and medications used for the treatment of infectious diseases caused by bacteria, viruses, fungi, or parasites. This market encompasses various therapeutic areas such as antibiotics, antivirals, antifungals, and antiparasitics. The Anti-Infective Drugs market has been witnessing steady growth due to factors such as the increasing prevalence of infectious diseases, the emergence of drug-resistant strains, and the growing global population. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, but the market in Asia Pacific is expected to witness substantial growth in the coming years.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Drugs for Anti-Infective, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Drugs for Anti-Infective market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Drugs for Anti-Infective market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Drugs for Anti-Infective sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Drugs for Anti-Infective covered in this report include GlaxoSmithKline, Merck, Pfizer, Novartis AG, Gilead Sciences, Abbott, Sanofi-Aventis, Bristol-Myers Squibb and Johnson, etc.
The global Drugs for Anti-Infective market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Merck
Pfizer
Novartis AG
Gilead Sciences
Abbott
Sanofi-Aventis
Bristol-Myers Squibb
Johnson
Roche Pharma AG
Nanosphere
NanoViricides
Novabay Pharmaceuticals
Obetech
Optimer Pharmaceuticals
Basilea Pharmaceutica AG
Daiichi Sankyo
Global Drugs for Anti-Infective market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Drugs for Anti-Infective market, Segment by Type:
OTC
Rx Drugs
Global Drugs for Anti-Infective market, by Application
Hospital
Drugs Store
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Drugs for Anti-Infective companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of Drugs for Anti-Infective
1.1 Drugs for Anti-Infective Market Overview
1.1.1 Drugs for Anti-Infective Product Scope
1.1.2 Drugs for Anti-Infective Market Status and Outlook
1.2 Global Drugs for Anti-Infective Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Drugs for Anti-Infective Market Size by Region (2018-2029)
1.4 Global Drugs for Anti-Infective Historic Market Size by Region (2018-2023)
1.5 Global Drugs for Anti-Infective Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Drugs for Anti-Infective Market Size (2018-2029)
1.6.1 North America Drugs for Anti-Infective Market Size (2018-2029)
1.6.2 Europe Drugs for Anti-Infective Market Size (2018-2029)
1.6.3 Asia-Pacific Drugs for Anti-Infective Market Size (2018-2029)
1.6.4 Latin America Drugs for Anti-Infective Market Size (2018-2029)
1.6.5 Middle East & Africa Drugs for Anti-Infective Market Size (2018-2029)
2 Drugs for Anti-Infective Market by Type
2.1 Introduction
2.1.1 OTC
2.1.2 Rx Drugs
2.2 Global Drugs for Anti-Infective Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Drugs for Anti-Infective Historic Market Size by Type (2018-2023)
2.2.2 Global Drugs for Anti-Infective Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Drugs for Anti-Infective Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Drugs for Anti-Infective Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Drugs for Anti-Infective Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Drugs for Anti-Infective Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Drugs for Anti-Infective Revenue Breakdown by Type (2018-2029)
3 Drugs for Anti-Infective Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Drugs Store
3.1.3 Other
3.2 Global Drugs for Anti-Infective Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Drugs for Anti-Infective Historic Market Size by Application (2018-2023)
3.2.2 Global Drugs for Anti-Infective Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Drugs for Anti-Infective Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Drugs for Anti-Infective Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Drugs for Anti-Infective Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Drugs for Anti-Infective Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Drugs for Anti-Infective Revenue Breakdown by Application (2018-2029)
4 Drugs for Anti-Infective Competition Analysis by Players
4.1 Global Drugs for Anti-Infective Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Drugs for Anti-Infective as of 2022)
4.3 Date of Key Players Enter into Drugs for Anti-Infective Market
4.4 Global Top Players Drugs for Anti-Infective Headquarters and Area Served
4.5 Key Players Drugs for Anti-Infective Product Solution and Service
4.6 Competitive Status
4.6.1 Drugs for Anti-Infective Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Profile
5.1.2 GlaxoSmithKline Main Business
5.1.3 GlaxoSmithKline Drugs for Anti-Infective Products, Services and Solutions
5.1.4 GlaxoSmithKline Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.1.5 GlaxoSmithKline Recent Developments
5.2 Merck
5.2.1 Merck Profile
5.2.2 Merck Main Business
5.2.3 Merck Drugs for Anti-Infective Products, Services and Solutions
5.2.4 Merck Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.2.5 Merck Recent Developments
5.3 Pfizer
5.3.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Drugs for Anti-Infective Products, Services and Solutions
5.3.4 Pfizer Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis AG Recent Developments
5.4 Novartis AG
5.4.1 Novartis AG Profile
5.4.2 Novartis AG Main Business
5.4.3 Novartis AG Drugs for Anti-Infective Products, Services and Solutions
5.4.4 Novartis AG Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis AG Recent Developments
5.5 Gilead Sciences
5.5.1 Gilead Sciences Profile
5.5.2 Gilead Sciences Main Business
5.5.3 Gilead Sciences Drugs for Anti-Infective Products, Services and Solutions
5.5.4 Gilead Sciences Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.5.5 Gilead Sciences Recent Developments
5.6 Abbott
5.6.1 Abbott Profile
5.6.2 Abbott Main Business
5.6.3 Abbott Drugs for Anti-Infective Products, Services and Solutions
5.6.4 Abbott Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.6.5 Abbott Recent Developments
5.7 Sanofi-Aventis
5.7.1 Sanofi-Aventis Profile
5.7.2 Sanofi-Aventis Main Business
5.7.3 Sanofi-Aventis Drugs for Anti-Infective Products, Services and Solutions
5.7.4 Sanofi-Aventis Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.7.5 Sanofi-Aventis Recent Developments
5.8 Bristol-Myers Squibb
5.8.1 Bristol-Myers Squibb Profile
5.8.2 Bristol-Myers Squibb Main Business
5.8.3 Bristol-Myers Squibb Drugs for Anti-Infective Products, Services and Solutions
5.8.4 Bristol-Myers Squibb Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.8.5 Bristol-Myers Squibb Recent Developments
5.9 Johnson
5.9.1 Johnson Profile
5.9.2 Johnson Main Business
5.9.3 Johnson Drugs for Anti-Infective Products, Services and Solutions
5.9.4 Johnson Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.9.5 Johnson Recent Developments
5.10 Roche Pharma AG
5.10.1 Roche Pharma AG Profile
5.10.2 Roche Pharma AG Main Business
5.10.3 Roche Pharma AG Drugs for Anti-Infective Products, Services and Solutions
5.10.4 Roche Pharma AG Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.10.5 Roche Pharma AG Recent Developments
5.11 Nanosphere
5.11.1 Nanosphere Profile
5.11.2 Nanosphere Main Business
5.11.3 Nanosphere Drugs for Anti-Infective Products, Services and Solutions
5.11.4 Nanosphere Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.11.5 Nanosphere Recent Developments
5.12 NanoViricides
5.12.1 NanoViricides Profile
5.12.2 NanoViricides Main Business
5.12.3 NanoViricides Drugs for Anti-Infective Products, Services and Solutions
5.12.4 NanoViricides Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.12.5 NanoViricides Recent Developments
5.13 Novabay Pharmaceuticals
5.13.1 Novabay Pharmaceuticals Profile
5.13.2 Novabay Pharmaceuticals Main Business
5.13.3 Novabay Pharmaceuticals Drugs for Anti-Infective Products, Services and Solutions
5.13.4 Novabay Pharmaceuticals Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.13.5 Novabay Pharmaceuticals Recent Developments
5.14 Obetech
5.14.1 Obetech Profile
5.14.2 Obetech Main Business
5.14.3 Obetech Drugs for Anti-Infective Products, Services and Solutions
5.14.4 Obetech Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.14.5 Obetech Recent Developments
5.15 Optimer Pharmaceuticals
5.15.1 Optimer Pharmaceuticals Profile
5.15.2 Optimer Pharmaceuticals Main Business
5.15.3 Optimer Pharmaceuticals Drugs for Anti-Infective Products, Services and Solutions
5.15.4 Optimer Pharmaceuticals Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.15.5 Optimer Pharmaceuticals Recent Developments
5.16 Basilea Pharmaceutica AG
5.16.1 Basilea Pharmaceutica AG Profile
5.16.2 Basilea Pharmaceutica AG Main Business
5.16.3 Basilea Pharmaceutica AG Drugs for Anti-Infective Products, Services and Solutions
5.16.4 Basilea Pharmaceutica AG Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.16.5 Basilea Pharmaceutica AG Recent Developments
5.17 Daiichi Sankyo
5.17.1 Daiichi Sankyo Profile
5.17.2 Daiichi Sankyo Main Business
5.17.3 Daiichi Sankyo Drugs for Anti-Infective Products, Services and Solutions
5.17.4 Daiichi Sankyo Drugs for Anti-Infective Revenue (US$ Million) & (2018-2023)
5.17.5 Daiichi Sankyo Recent Developments
6 North America
6.1 North America Drugs for Anti-Infective Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Drugs for Anti-Infective Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Anti-Infective Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Drugs for Anti-Infective Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Anti-Infective Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Drugs for Anti-Infective Market Dynamics
11.1 Drugs for Anti-Infective Industry Trends
11.2 Drugs for Anti-Infective Market Drivers
11.3 Drugs for Anti-Infective Market Challenges
11.4 Drugs for Anti-Infective Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’